Get the Stockscreener App
3.38
6.54%
-0.29
Briacell Therapeutics Corp stock is traded at $3.38, with a volume of 47,272.
It is down -6.54% in the last 24 hours and down -31.94% over the past month.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
See More
Previous Close:
$3.67
Open:
$3.61
24h Volume:
47,272
Relative Volume:
0.13
Market Cap:
$13.72M
Revenue:
-
Net Income/Loss:
$-16.60M
P/E Ratio:
-3.7978
EPS:
-0.89
Net Cash Flow:
$-23.48M
1W Performance:
-24.45%
1M Performance:
-31.94%
6M Performance:
-67.72%
1Y Performance:
-93.41%
1-Day Range:
$3.3814
$3.7386
1-Week Range:
$3.3814
$4.50
52-Week Range:
$3.33
$52.93
Briacell Therapeutics Corp Stock (BCTX) Company Profile
Name
Briacell Therapeutics Corp
Sector
Industry
Phone
(604) 921-1810
Address
3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER
Compare BCTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCTX
Briacell Therapeutics Corp
|
3.3814 | 13.72M | 0 | -16.60M | -23.48M | -0.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.10 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.58 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
633.30 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.11 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.75 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-22 | Initiated | H.C. Wainwright | Buy |
Briacell Therapeutics Corp Stock (BCTX) Latest News
BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Significant Increase in Short Interest - Defense World
BriaCell Therapeutics (NASDAQ:BCTX) versus Actinium Pharmaceuticals (NYSE:ATNM) Critical Analysis - Defense World
(BCT) Equity Trading Insights (BCT:CA) - Stock Traders Daily
(BCT) Market Performance Analysis (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics Corp (NASDAQ: BCTX) – An Analysis Is What You Need - Stocks Register
(BCT) Investment Analysis (BCT:CA) - Stock Traders Daily
(BCT) Trading Advice (BCT:CA) - Stock Traders Daily
BriaCell Therapeutics: A Biotech Stock on the Brink of a Turnaround? - HPBL
Biotechs on the Brink: 2 Stocks With Huge Potential - MarketBeat
BriaCell regains Nasdaq compliance with bid price By Investing.com - Investing.com Australia
BriaCell regains Nasdaq compliance with bid price - MSN
Briacell Therapeutics CorpRegains Compliance With Nasdaq Minimum Bid Price Requirement - Marketscreener.com
BriaCell Announces Positive Shareholder Meeting Results - MSN
BriaCell announces public offering of common shares By Investing.com - Investing.com Nigeria
BriaCell Therapeutics (NASDAQ:BCTXW) Trading Up 0.2% – Time to Buy? - Defense World
BriaCell Therapeutics Closes Public Offering, Raises $3.05 MillionUnited States Securities and Exchange Commission, Washington, D.C. – February 3, 2025, BriaCell Therapeutics Corp. recently concluded a successful public offering. The Canadian biotech - Armenian Reporter
Equities Analysts Set Expectations for TSE:BCT Q2 Earnings - MarketBeat
BriaCell announces public offering of common shares - MSN
BriaCell immunotherapy destroys metastatic breast cancer tumor - MSN
BriaCell Therapeutics (NASDAQ:BCTX) Price Target Raised to $32.00 - Armenian Reporter
HC Wainwright Has Bullish Estimate for BCTX Q2 Earnings - Defense World
HC Wainwright Has Bullish Forecast for TSE:BCT Q2 Earnings - Defense World
BriaCell Therapeutics Announces Closing of Public Offering - GlobeNewswire
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting - GlobeNewswire
BriaCell's Board Secures Massive 88% Shareholder Approval at Annual Meeting - StockTitan
BriaCell Therapeutics Secures $3.05 Million in Public Offering - TipRanks
Briacell Therapeutics Announces Closing Of Public Offering -February 05, 2025 at 04:19 pm EST - Marketscreener.com
BriaCell Therapeutics Announces Closing of Public Offering - Benzinga
Cancer Immunotherapy Pioneer BriaCell Secures Critical $3.05M Funding to Advance Treatment Development - StockTitan
BriaCell Therapeutics stock rises on positive clinical trial results - MSN
United Therapeutics president sells $3.5m in stock - MSN
BriaCell Stock Climbs After ‘Unprecedented’ Immunotherapy Response In Breast Cancer Patient, Retail Exudes Optimism - MSN
BriaCell immunotherapy destroys metastatic breast cancer tumor | 2025-02-03 | Investing News - Stockhouse Publishing
H.C. Wainwright raises Briacell stock target to $32 on trial success - Investing.com
BriaCell Therapeutics (NASDAQ:BCTX) Given New $32.00 Price Target at HC Wainwright - Defense World
BriaCell Therapeutics slumps 20%, prices $3M stock offering - MSN
ForexTV | Small Business Resources - ForexTV.com
BriaCell Therapeutics Announces $3.05 Million Public Offering - TipRanks
Briacell Therapeutics Prices Public Offering Of 762,500 Shares At $4 Each -February 03, 2025 at 08:04 pm EST - Marketscreener.com
BriaCell's $3.05M Capital Raise: Strategic Move or Dilution Concern? - StockTitan
Wavelo Secures Four-Year Contract Renewal with EchoStar - The Globe and Mail
BriaCell Therapeutics Announces Pricing of Public Offering - Yahoo Finance
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™ - GlobeNewswire
Briacell Therapeutics Announces Proposed Public Offering Of Common Shares -February 03, 2025 at 05:36 pm EST - Marketscreener.com
BriaCell Therapeutics Shares Hit Record Low After Public Offering News - MarketWatch
BriaCell Therapeutics Announces Public Offering to Fuel Growth - TipRanks
Briacell Therapeutics Corp Stock (BCTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):